Together, these results are consistent with the cardioprotective effects of roflumilast, suggesting that reducing the abundance of PDE4D may provide an effective strategy to protect against cardiac hypertrophy and mitochondrial dysfunction by modulating SIRT1-mediated mitophagy. Here, SIRT1 is linked to cardiac hypertrophy.